NASDAQ:APEN

Apollo Endosurgery - APEN Stock Forecast, Price & News

$10.01

0.00 (0.00%)

(As of 12/7/2022 12:08 PM ET)

Add

Compare

Today's Range: $10.00
▼
$10.04
50-Day Range: $4.93
▼
$10.14
52-Week Range: $3.49
▼
$10.30

Volume: 32,182 shs
Average Volume: 1.86 million shs
Market Capitalization: $416.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.25

Apollo Endosurgery MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 12.3% Upside
$11.25 Price Target
Short Interest: Bearish
2.76% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.12
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.97) to ($0.86) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

896th out of 1,023 stocks

Surgical & Medical Instruments Industry

89th out of 102 stocks

2.3

Analyst's Opinion

Consensus Rating
Apollo Endosurgery has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.25, Apollo Endosurgery has a forecasted upside of 12.3% from its current price of $10.02.
Amount of Analyst Coverage
Apollo Endosurgery has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
2.76% of the outstanding shares of Apollo Endosurgery have been sold short.
Short Interest Ratio / Days to Cover
Apollo Endosurgery has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Apollo Endosurgery has recently increased by 3.60%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Apollo Endosurgery does not currently pay a dividend.
Dividend Growth
Apollo Endosurgery does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for APEN.

2.8

News and Social Media Coverage

News Sentiment
Apollo Endosurgery has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Apollo Endosurgery this week, compared to 1 article on an average week.
Search Interest
7 people have searched for APEN on MarketBeat in the last 30 days.
MarketBeat Follows
2 people have added Apollo Endosurgery to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Apollo Endosurgery insiders have not sold or bought any company stock.
Percentage Held by Insiders
17.30% of the stock of Apollo Endosurgery is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
74.24% of the stock of Apollo Endosurgery is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Apollo Endosurgery are expected to grow in the coming year, from ($0.97) to ($0.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Apollo Endosurgery is -9.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Apollo Endosurgery is -9.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Apollo Endosurgery has a P/B Ratio of 6.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Apollo Endosurgery (NASDAQ:APEN) Stock

Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. The company offers OverStitch and OverStitch Sx Endoscopic Suturing Systems that enable advanced endoscopic procedures by allowing physicians to sutures and secure the approximation of tissue through a flexible endoscope. It also provides Orbera, an intragastric balloon system that reduces stomach capacity causing patients to consume less following the procedure, as well as delays gastric content emptying under the Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System brands. Additionally, the company offers X-Tack Endoscopic HeliX Tacking System, a suture-based device for closing and healing defects in the lower and upper gastrointestinal tract. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Australia, Costa Rica, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.

Receive APEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollo Endosurgery and its competitors with MarketBeat's FREE daily newsletter.

APEN Stock News Headlines

December 5, 2022 | wsj.com

SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Apollo Endosurgery, Inc. - APEN

December 3, 2022 | americanbankingnews.com

Apollo Endosurgery (NASDAQ:APEN) Stock Rating Lowered by Lake Street Capital

November 30, 2022 | bizjournals.com

Boston Scientific shells out $615M for gastro device firm

November 29, 2022 | nasdaq.com

Boston Scientific to buy Apollo Endosurgery for $417 million

November 29, 2022 | reuters.com

Boston Scientific to acquire Apollo Endosurgery in $615 mln deal

November 29, 2022 | finance.yahoo.com

Apollo Endosurgery to be Acquired by Boston Scientific

November 29, 2022 | finance.yahoo.com

Boston Scientific to acquire Apollo Endosurgery for $615 million in cash

November 21, 2022 | finance.yahoo.com

Apollo Endosurgery Completes Transition to European MDR Requirements for the OverStitch Systems, BIB and Orbera 365 intragastric balloons, and OverTube.

November 8, 2022 | finance.yahoo.com

Apollo Endosurgery, Inc. (NASDAQ:APEN) is largely controlled by institutional shareholders who own 58% of the company

November 7, 2022 | finance.yahoo.com

Apollo Endosurgery to Participate in Upcoming Investor Conferences

November 1, 2022 | finance.yahoo.com

Apollo Endosurgery, Inc. Reports Record $19.6 million Global Revenue in Third Quarter 2022

October 18, 2022 | finance.yahoo.com

Apollo Endosurgery to Report Third Quarter Results on November 1, 2022

October 12, 2022 | nasdaq.com

Investors in Apollo Endosurgery (NASDAQ:APEN) have made a favorable return of 92% over the past three years

October 10, 2022 | msn.com

Short Volatility Alert: Apollo Endosurgery, Inc.

September 26, 2022 | finance.yahoo.com

Apollo Endosurgery, Inc. (APEN)

September 17, 2022 | investing.com

Apollo Tyres Ltd (APLO)

September 6, 2022 | finance.yahoo.com

MIMEDX Announces Leadership Transition

August 31, 2022 | finance.yahoo.com

Endoscopic Sleeve Gastroplasty (ESG) Procedure Featured as a "Top 10" Paper at the IFSO 2022 World Congress in Miami

August 25, 2022 | finance.yahoo.com

Apollo Endosurgery, Inc. (NASDAQ:APEN) insider upped their holding by 160% earlier this year

August 4, 2022 | finance.yahoo.com

Apollo Endosurgery (NASDAQ:APEN) hikes 14% this week, taking three-year gains to 156%

August 4, 2022 | seekingalpha.com

Apollo Endosurgery: Collect Shares At A Discount Following Q2 Earnings

August 2, 2022 | finance.yahoo.com

Apollo Endosurgery, Inc. Reports Record Global Revenue in Second Quarter 2022

July 29, 2022 | finanznachrichten.de

Apollo Endosurgery, Inc.: Apollo Endosurgery Announces Publication in the Lancet of Landmark Study for the Endoscopic Sleeve Gastroplasty Procedure

July 29, 2022 | finance.yahoo.com

Apollo Endosurgery Announces Publication in the Lancet of Landmark Study for the Endoscopic Sleeve Gastroplasty Procedure

July 21, 2022 | finance.yahoo.com

Apollo Endosurgery to Report Second Quarter Results on August 2, 2022

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive APEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apollo Endosurgery and its competitors with MarketBeat's FREE daily newsletter.

APEN Company Calendar

Last Earnings: 10/31/2021
Today: 12/07/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/28/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:APEN
CUSIP: N/A
CIK: 1251769
Web: www.apolloendo.com
Phone: (512) 279-5100
Fax: 858-678-0900
Employees: 202
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $11.25
High Stock Price Forecast: $13.00
Low Stock Price Forecast: $10.00
Forecasted Upside/Downside: +12.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,680,000.00
Net Margins: -56.74%
Pretax Margin: -56.26%
Return on Equity: -78.73%
Return on Assets: -32.99%

Debt

Debt-to-Equity Ratio: 1.26
Current Ratio: 6.00
Quick Ratio: 4.98

Sales & Book Value

Annual Sales: $62.99 million
Price / Sales: 6.62
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.55 per share
Price / Book: 6.46

Miscellaneous

Outstanding Shares: 41,630,000
Free Float: 34,431,000
Market Cap: $416.72 million
Optionable: Not Optionable
Beta: 2.39

Key Executives

Mr. Charles S. McKhann (Age 53)
CEO, Pres & Director
Comp: $963.53k

Mr. Jeffrey G. Black (Age 53)
CFO, Sec. & Treasurer
Comp: $524.02k

Mr. John J. Molesphini (Age 64)
Exec. VP of Operations
Comp: $502.58k

Dr. Sergey Kantsevoy M.D.
Co-Founder and Innovation Partner

Mr. Anthony Kalloo M.D.
Co-Founder and Innovation Partner

Dr. Robert Hawes M.D.
Co-Founder and Innovation Partner

Dr. Peter Benjamin Cotton M.D.
Co-Founder and Innovation Partner

Dr. Christopher J. Gostout M.D. (Age 71)
Co-Founder & Chief Medical Officer

Mr. Sydney Chung M.D.
Co-Founder and Innovation Partner

Dr. Pankaj Jay Pasricha FACP
M.D., MBBS, Co-Founder

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

APEN Stock - Frequently Asked Questions

Should I buy or sell Apollo Endosurgery stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APEN shares.
View APEN analyst ratings or view top-rated stocks.
What is Apollo Endosurgery's stock price forecast for 2023?: 3 brokerages have issued 12-month target prices for Apollo Endosurgery's shares. Their APEN share price forecasts range from $10.00 to $13.00. On average, they anticipate the company's share price to reach $11.25 in the next twelve months. This suggests a possible upside of 12.4% from the stock's current price.
View analysts price targets for APEN or view top-rated stocks among Wall Street analysts.
How have APEN shares performed in 2022?: Apollo Endosurgery's stock was trading at $8.43 at the beginning of 2022. Since then, APEN stock has increased by 18.7% and is now trading at $10.01.
View the best growth stocks for 2022 here.
When is Apollo Endosurgery's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our APEN earnings forecast.
How were Apollo Endosurgery's earnings last quarter?: Apollo Endosurgery, Inc. (NASDAQ:APEN) released its earnings results on Sunday, October, 31st. The biotechnology company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.05. The biotechnology company earned $16.35 million during the quarter, compared to analysts' expectations of $16.20 million. Apollo Endosurgery had a negative trailing twelve-month return on equity of 78.73% and a negative net margin of 56.74%. During the same period in the previous year, the firm earned ($0.11) earnings per share.
What guidance has Apollo Endosurgery issued on next quarter's earnings?: Apollo Endosurgery updated its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $75.00 million-$76.00 million, compared to the consensus revenue estimate of $73.95 million.

What other stocks do shareholders of Apollo Endosurgery own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Apollo Endosurgery investors own include Obalon Therapeutics (OBLN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX), OPKO Health (OPK), Pfizer (PFE), Sunesis Pharmaceuticals (SNSS), Biocept (BIOC), Co-Diagnostics (CODX) and Second Sight Medical Products (EYES).
What is Apollo Endosurgery's stock symbol?: Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."
Who are Apollo Endosurgery's major shareholders?: Apollo Endosurgery's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (6.80%), Gagnon Securities LLC (4.29%), Vanguard Group Inc. (3.27%), Silverarc Capital Management LLC (2.79%), Russell Investments Group Ltd. (2.34%) and Parkman Healthcare Partners LLC (1.58%). Insiders that own company stock include Chas Mckhann, Cpmg Inc, David Pacitti, Jeffrey G Black, John R Barr, Neil Gagnon and R Kent Mcgaughy Jr.
View institutional ownership trends.
How do I buy shares of Apollo Endosurgery?: Shares of APEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Apollo Endosurgery's stock price today?: One share of APEN stock can currently be purchased for approximately $10.01.
How much money does Apollo Endosurgery make?: Apollo Endosurgery (NASDAQ:APEN) has a market capitalization of $416.76 million and generates $62.99 million in revenue each year. The biotechnology company earns $-24,680,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.
How many employees does Apollo Endosurgery have?: The company employs 202 workers across the globe.
How can I contact Apollo Endosurgery?: Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The official website for the company is www.apolloendo.com. The biotechnology company can be reached via phone at (512) 279-5100, via email at investor-relations@apolloendo.com, or via fax at 858-678-0900.

This page (NASDAQ:APEN) was last updated on 12/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial